Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study

Abstract

Hanhui Zou, Liming Xia, Gu Jin, Hao Wu, Wenkang Qian, Dongdong Jia, Haichao Xu, Tao Li Bone and Soft Tissue Surgery, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, 310022, People’s Republic of ChinaCorrespondence: Tao Li, Email [email protected]: Retrospective study on the safety and efficacy of anlotinib in the treatment of advanced leiomyosarcoma in real-world.Methods: Clinical data were collected from patients suffered from advanced leiomyosarcoma who received anlotinib treatment in Cancer Hospital of the University of Chinese Academy of Sciences from January 2018 to December 2020. Objective response rate (ORR) and disease control rate (DCR) were analyzed according to the RECIST 1.1 criteria. The progression free survival (PFS), overall survival (OS) and adverse reactions were recorded and calculated.Results: A total of 19 patients (14 female, 5 male) were enrolled, 3 (15.8%) achieved partial response (PR), 11 (57.9%) achieved stable disease (SD), with an ORR of 15.8%, a DCR of 73.7%, a median PFS of 4.1 months (95% CI: 3.0∼ 5.2) and a median OS of 23.5 months (95% CI: 14.2∼ 32.7). The majority of adverse events were grade 1/2, the most common grade 3/4 adverse events were hand-foot syndrome (12.5%), hypertension (5.3%) and oral ulcer (5.3%).Conclusion: Our results forecast that anlotinib is effective, safe and alternative in treatment of advanced leiomyosarcoma in real-world, combined with immunotherapy may become a potential treatment option. Further, more prospective randomized controlled trials are needed to confirm these findings.Keywords: leiomyosarcoma, anlotinib, efficacy, adverse events

Keywords

• leiomyosarcoma
• anlotinib
• efficacy
• adverse events. introduction